Form 4: Halozyme Therapeutics CEO Helen Torley Acquires Performance Stock Units
SEC Form 4 Filing
Halozyme Therapeutics' CEO, Helen Torley, acquired performance-based vesting stock units based on performance achieved during the period ending December 31, 2024.
Summary
- On February 12, 2025, Helen Torley, the President and CEO of Halozyme Therapeutics, acquired performance stock units (PSUs) that will convert to common stock.
- These PSUs were awarded on February 16, 2022, February 16, 2023, and February 23, 2024, with a performance measurement period ending December 31, 2024.
- The number of stock units that became eligible to vest was determined based on performance for the specified period.
- The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
- Torley acquired 24,957 units from the 2022 grant, 20,008 units from the 2023 grant, and 23,260 units from the 2024 grant, resulting in a total of 96,155 performance stock units.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive as it reflects the vesting of performance-based stock units, indicating that performance targets were met. This suggests confidence in the company's direction.
Positives
- The acquisition of performance stock units by the CEO suggests confidence in the company's performance and future prospects.
Risks
- The value of the stock units is contingent on continued service through the third anniversary of the grant date, meaning the CEO must remain with the company for the units to fully vest.
Future Outlook
The vesting of the performance stock units is contingent on continued service through the third anniversary of the grant date.
Industry Context
This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry.
Comparison to Industry Standards
- Performance-based equity compensation is a common practice among publicly traded companies, especially in the biotech industry, to align executive incentives with company performance.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar performance-based equity awards for their executives.
Stakeholder Impact
- The acquisition of performance stock units by the CEO can positively influence shareholder confidence, as it aligns management's interests with those of the shareholders.
Next Steps
- The acquired stock units will remain subject to a service-based requirement through the third anniversary of the PSU grant date.
Key Dates
| Date | Description |
|---|---|
| 2022-02-16 | Date of the first PSU grant to Helen Torley. |
| 2023-02-16 | Date of the second PSU grant to Helen Torley. |
| 2024-02-23 | Date of the third PSU grant to Helen Torley. |
| 2024-12-31 | End of the performance measurement period for the PSUs. |
| 2025-02-12 | Date of the transaction where Helen Torley acquired the performance stock units. |
| 2025-02-14 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.